AbbVie falls 0.9% as clinical and conference updates mark the week

What happened

AbbVie (ABBV) fell 0.9% to close at $282.78 on October 19, 2026, as investors absorbed Phase 2a Crohn’s results and a slate of oncology presentations ahead of its next earnings report. The session was an ordinary one for the stock; present the items reported as the main developments around the company rather than the proven cause of the price move. News included Phase 2a results for ABBV-466 in moderate to severe Crohn's disease. Those results showed higher endoscopic remission rates at Week 12 versus anti-IL-23 p19 or anti-α4β7 monotherapies, and the treatment difference increased by Week 24, according to a PRNewsWire release. Gene expression analysis also indicated effects on intestinal tissue in treated patients.

AbbVie said it will present new and updated data across seven oncology assets at the 2026 ESMO Congress, covering lung, colorectal, ovarian, prostate and gastric cancers. The company highlighted next-generation ADCs, combination approaches, biomarker findings and longer-term survival data, according to GuruFocus and PRNewsWire. Analysts at Zacks Investment Research flagged that AbbVie's neuroscience franchise is projected to target nearly 16% revenue growth in the third quarter, helped in part by newer Parkinson's therapies ahead of the company's Q3 results.

How big was the move

The stock fell 0.9% on the day and rose 0.6% over the last five sessions. Trading volume was 0.8 times its 20-day average and the session's size equaled 0.7 times a typical daily move for this stock, consistent with an ordinary session. The S&P 500 rose 0.4% on the day while the healthcare sector median rose 1.0%, leaving the stock 1.9 percentage points worse than the sector median. AbbVie's market sensitivity is low, with a beta of 0.05, meaning the stock tends to move less than the market. The company’s market value stood at $504.37 billion.

The technical picture

The stock sat 4.4% above its 20-day moving average, 7.4% above its 50-day moving average and 20.7% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 84 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 66, in a neutral range. Over one month the stock rose 7.1%, over three months it rose 10.4% and over one year it rose 24.6%, which is 8.6 percentage points ahead of the S&P 500. The stock was 3.0% below its 52-week high, with volatility of 22% annualized over 60 days, a level lower than 57% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, AbbVie reported revenue of $64.39 billion, which grew 10.4% from a year earlier, and diluted earnings per share of $3.55, which rose 68.1% from a year earlier. Gross margin was 71.5% versus 70.9% a year earlier, and operating margin was 29.3% versus 18.8% a year earlier. Free-cash-flow margin was 30.6% and return on invested capital was 13.5%. Balance-sheet leverage was net debt of 3.0 times EBITDA. Valuation stood at 79.7 times trailing earnings and 20.3 times price to forward earnings, with a free-cash-flow yield of 3.9%. The trailing multiple is higher than 76% of its own readings over the past five years; the five-year median is 48.6 times earnings.

Earnings and analyst expectations

AbbVie is scheduled to report next on October 30, 2026. Its last report, on July 31, 2026, delivered earnings per share of $3.65 against $3.61 expected, 1.1% above estimates. That marked six consecutive quarters beating estimates, with an average surprise of 2.7% above estimates over the last four reports. The typical two-day reaction after recent reports was that the stock rose 0.8%. Analysts providing ratings number 44; the consensus rating is Buy, with 73% of those ratings classified as Buy. The consensus price target is $292.21, which is 3.3% above the closing price reported on October 19, 2026.

What to watch

• October 30, 2026: AbbVie's next quarterly earnings report and management commentary on guidance and product performance
• Details and follow-up analyses from the Phase 2a ABBV-466 Crohn's trial reported by PRNewsWire, including Week 12 and Week 24 endoscopic remission rates
• New and updated presentations across seven oncology assets at the 2026 ESMO Congress, reported by GuruFocus and PRNewsWire
• Neuroscience revenue projections for Q3 flagged by Zacks Investment Research, including contributions from Parkinson's therapies
• Any updates to analyst estimates or consensus price targets following the ESMO presentations and the upcoming earnings report